The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...

Analysts say the two new indications should help Eylea HD as Regeneron battles for market share with Roche’s Vabysmo.

The FDA also approved an every 4 week dosing regimen across all approved indications for patients who may not maintain a response on extended dosing intervals following successful initial treatment.

Treatment with high dose aflibercept 8 mg can lead to similar visual outcomes with fewer injections for patients with RVO.

NEW YORK, July 30 (Reuters) - Roche Holding AG's eye disease drug Lucentis proved effective in helping to improve vision in patients suffering from a condition known as central retinal vein occlusion, ...

If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period – halving the number of injections that are indicated ...

Ronnie Uhlmann is afflicted with branch retinal vein occlusion, which, her husband Peter, a retired physician said, means the ...

The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...